Collplant Biotechnologies Ltd (CLGN)

$5.12

-0.15

(-2.85%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $5.00
    $5.32
    $5.12
    downward going graph

    2.34%

    Downside

    Day's Volatility :6.02%

    Upside

    3.76%

    downward going graph
  • $4.10
    $7.84
    $5.12
    downward going graph

    19.92%

    Downside

    52 Weeks Volatility :47.7%

    Upside

    34.69%

    downward going graph

Returns

PeriodCollplant Biotechnologies LtdIndex (Russel 2000)
3 Months
-0.19%
0.0%
6 Months
2.2%
0.0%
1 Year
-32.59%
0.0%
3 Years
-71.28%
-22.3%

Highlights

Market Capitalization
60.4M
Book Value
$1.81
Earnings Per Share (EPS)
-1.53
Wall Street Target Price
12.5
Profit Margin
0.0%
Operating Margin TTM
-1769.48%
Return On Assets TTM
-33.77%
Return On Equity TTM
-61.55%
Revenue TTM
689.0K
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-97.6%
Gross Profit TTM
13.6M
EBITDA
-17.3M
Diluted Eps TTM
-1.53
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.25
EPS Estimate Next Year
-0.39
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Collplant Biotechnologies Ltd(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 144.14%

Current $5.12
Target $12.50

Company Financials

FY18Y/Y Change
Revenue
4.8M
↑ 897.75%
Net Income
-6.2M
↑ 3.27%
Net Profit Margin
-130.5%
↑ 1130.34%
FY19Y/Y Change
Revenue
2.3M
↓ 51.59%
Net Income
-14.7M
↑ 135.19%
Net Profit Margin
-634.04%
↓ 503.54%
FY20Y/Y Change
Revenue
6.1M
↑ 164.75%
Net Income
-5.8M
↓ 60.48%
Net Profit Margin
-94.64%
↑ 539.4%
FY21Y/Y Change
Revenue
15.6M
↑ 154.86%
Net Income
409.0K
↓ 107.04%
Net Profit Margin
2.61%
↑ 97.25%
FY22Y/Y Change
Revenue
299.0K
↓ 98.09%
Net Income
-16.8M
↓ 4196.09%
Net Profit Margin
-5.6K%
↓ 5605.62%
FY23Y/Y Change
Revenue
11.0M
↑ 3565.22%
Net Income
-7.0M
↓ 58.1%
Net Profit Margin
-64.05%
↑ 5538.96%
Q1 FY23Q/Q Change
Revenue
433.0K
↑ 0.0%
Net Income
-3.9M
↑ 0.0%
Net Profit Margin
-903.23%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
10.2M
↑ 2251.96%
Net Income
5.8M
↓ 247.33%
Net Profit Margin
56.58%
↑ 959.81%
Q3 FY23Q/Q Change
Revenue
43.0K
↓ 99.58%
Net Income
-4.4M
↓ 175.96%
Net Profit Margin
-10.2K%
↓ 10235.65%
Q4 FY23Q/Q Change
Revenue
299.0K
↑ 595.35%
Net Income
-4.7M
↑ 7.13%
Net Profit Margin
-1.6K%
↑ 8610.84%
Q1 FY24Q/Q Change
Revenue
249.0K
↓ 16.72%
Net Income
-4.2M
↓ 10.22%
Net Profit Margin
-1.7K%
↓ 122.53%
Q2 FY24Q/Q Change
Revenue
249.0K
↑ 0.0%
Net Income
-4.2M
↑ 0.0%
Net Profit Margin
-1.7K%
↑ 0.0%
FY18Y/Y Change
Total Assets
9.0M
↑ 12.15%
Total Liabilities
4.3M
↓ 21.37%
FY19Y/Y Change
Total Assets
10.8M
↑ 18.81%
Total Liabilities
6.7M
↑ 55.35%
FY20Y/Y Change
Total Assets
10.8M
↑ 0.83%
Total Liabilities
6.4M
↓ 4.5%
FY21Y/Y Change
Total Assets
51.2M
↑ 372.5%
Total Liabilities
6.1M
↓ 4.1%
FY22Y/Y Change
Total Assets
37.8M
↓ 26.27%
Total Liabilities
5.5M
↓ 10.09%
FY23Y/Y Change
Total Assets
34.1M
↓ 9.64%
Total Liabilities
5.8M
↑ 5.45%
Q1 FY23Q/Q Change
Total Assets
35.8M
↑ 0.0%
Total Liabilities
5.9M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
41.6M
↑ 16.25%
Total Liabilities
5.5M
↓ 5.78%
Q3 FY23Q/Q Change
Total Assets
37.6M
↓ 9.65%
Total Liabilities
5.2M
↓ 6.69%
Q4 FY23Q/Q Change
Total Assets
34.1M
↓ 9.14%
Total Liabilities
5.8M
↑ 12.13%
Q1 FY24Q/Q Change
Total Assets
26.6M
↓ 22.15%
Total Liabilities
5.8M
↑ 0.88%
Q2 FY24Q/Q Change
Total Assets
26.6M
↑ 0.0%
Total Liabilities
5.8M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-1.2M
↓ 75.93%
Investing Cash Flow
-832.0K
↑ 555.12%
Financing Cash Flow
2.6M
↓ 71.76%
FY19Y/Y Change
Operating Cash Flow
-5.7M
↑ 360.42%
Investing Cash Flow
-1.5M
↑ 75.6%
Financing Cash Flow
5.4M
↑ 105.5%
FY20Y/Y Change
Operating Cash Flow
-4.5M
↓ 21.95%
Investing Cash Flow
-519.0K
↓ 64.48%
Financing Cash Flow
4.5M
↓ 17.47%
FY21Y/Y Change
Operating Cash Flow
2.5M
↓ 156.19%
Investing Cash Flow
-31.6M
↑ 5980.15%
Financing Cash Flow
38.8M
↑ 768.09%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.5M
↑ 0.0%
Investing Cash Flow
-396.0K
↑ 30.26%
Financing Cash Flow
803.0K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.7M
↑ 8.52%
Investing Cash Flow
-396.0K
↑ 0.0%
Financing Cash Flow
89.0K
↓ 88.92%

Technicals Summary

Sell

Neutral

Buy

Collplant Biotechnologies Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Collplant Biotechnologies Ltd
Collplant Biotechnologies Ltd
10.82%
2.2%
-32.59%
-71.28%
30.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Collplant Biotechnologies Ltd
Collplant Biotechnologies Ltd
NA
NA
NA
-1.25
-0.62
-0.34
NA
1.81
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Collplant Biotechnologies Ltd
Collplant Biotechnologies Ltd
Buy
$60.4M
30.95%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Collplant Biotechnologies Ltd

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 299.0K → 249.0K (in $), with an average decrease of 8.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -4.68M → -4.21M (in $), with an average increase of 5.7% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 69.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 140.5%

Institutional Holdings

  • Parallel Advisors, LLC

    0.04%

Company Information

collplant is a regenerative medicine company focused on 3d bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. our products are based on our rhcollagen (recombinant human collagen) that is produced with collplant’s proprietary plant based genetic engineering technology. our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. our flagship rhcollagen bioink product line is ideal for 3d bioprinting of tissues and organs, and our unique vergenix line of rhcollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds. collplant is a public company listed on the tel aviv stock exchange and on nasdaq (clgn).

Organization
Collplant Biotechnologies Ltd
Employees
75
CEO
Mr. Yehiel Tal
Industry
Health Technology

Discover More

FAQs